IGF1 and Alzheimer disease: Stratifying by disease progression and genetic differences may expose currently unknown subtypes of AD that respond differently to IGF-1 supplementation, while more detailed analysis of CSF IGF-1 may encourage the development of techniques that increase CSF levels directly, and not by proxy of increasing serum levels.